Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12605000698673
Ethics application status
Approved
Date submitted
20/10/2005
Date registered
1/11/2005
Date last updated
19/01/2006
Type of registration
Retrospectively registered
Titles & IDs
Public title
Mifepristone ovarian function study
Query!
Scientific title
Study to determine the effect of one day administration of mifepristone and the same regimen followed by four days of daily administration of ethinyl oestradiol on ovulatory function and cervical mucus in women using Implanon
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
The effect of administering a progestogen receptor modulator with or without oestrogen on the ovarian function and quality of cervical mucus in women using the progestogen-only sub-dermal contraceptive, Implanon.
847
0
Query!
Condition category
Condition code
Other
914
914
0
0
Query!
Cervical (Cervix)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Eligible women will be randomised to either twice daily mifepristone 25mg on day 1 followed by 4 days of ethinyl oestradiol 20mcgs daily or placebo daily for 4 days Vaginal ultrasound, cervical mucus assessment and serum oestradiol and progestogen will be carried out at intervals for 4 weeks. Each woman will be in the study for four weeks.
Query!
Intervention code [1]
730
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
1189
0
Progestogen level >9nmol/L in any of the serum samples taken
Query!
Assessment method [1]
1189
0
Query!
Timepoint [1]
1189
0
Serum samples taken 2 days prior to treatment, 2 and 6 days after treatment has been started and then twice weekly for 3 weeks
Query!
Secondary outcome [1]
2175
0
Mean maximum size of ovarian follicles
Query!
Assessment method [1]
2175
0
Query!
Timepoint [1]
2175
0
Cervical mucus score assessed for the individual woman at each visit and the mean score at the end of the 4 week study.
Query!
Eligibility
Key inclusion criteria
Implanon users, who have been using Implanon for three months.Women who are willing to participate in a research investigation of new approaches to the therapy of breakthrough bleeding.Women who are prepared to have regular venepuncture, vaginal ultrasound and cervical mucus collection over a period of four weeks.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
45
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Pregnancy. Women who have currently or previously had Heart attack or strokeBlood clot in a veinHigh blood pressureSevere liver or kidney diseaseBlood pressure >160mm systolic or >95mm diastolicFocal migraineBreast cancer or any genital cancerWomen with known sensitivity to ethinyl oestradiol, or lactoseWomen taking phenytoin, carbamazepine or phenobarbitol or Women who are lactating.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Treatments will be packaged in identical bottles and placed according to randomisation code in sequentially numbered opaque envelopes.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A computer derived randomisation scheme in blocks with equal numbers in both groups
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Ultrasounds, cervical mucus assessment and serum oestradiol and progestogen levels will be carried out blind by a single operator. The randomisation code will not be broken until after the results are analysed
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
9/08/2005
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
1009
0
Charities/Societies/Foundations
Query!
Name [1]
1009
0
FPA Health Foundation
Query!
Address [1]
1009
0
Query!
Country [1]
1009
0
Australia
Query!
Primary sponsor type
Charities/Societies/Foundations
Query!
Name
FPA Health
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
870
0
None
Query!
Name [1]
870
0
None
Query!
Address [1]
870
0
Query!
Country [1]
870
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
2320
0
Sydney Centre for Reproductive Health Research
Query!
Ethics committee address [1]
2320
0
Query!
Ethics committee country [1]
2320
0
Australia
Query!
Date submitted for ethics approval [1]
2320
0
Query!
Approval date [1]
2320
0
Query!
Ethics approval number [1]
2320
0
Query!
Ethics committee name [2]
2321
0
Research Division of FPA Health
Query!
Ethics committee address [2]
2321
0
Query!
Ethics committee country [2]
2321
0
Australia
Query!
Date submitted for ethics approval [2]
2321
0
Query!
Approval date [2]
2321
0
Query!
Ethics approval number [2]
2321
0
Query!
Summary
Brief summary
The aim is to determine whether the administration of mifepristone alone or in combination with ethinyl oestradiol will effect the contraceptive efficacy of Implanon whose main mode of action is ovulation suppression and a secondary effect on cervical mucus making it impenatrable to sper. Both the treaments we will use have been shown to have a beneficial effect on bleeding patterns in women using progestogen-only contraceptive methods. Bleeding problems are the major reason for women discontinuing these highly effective contraceptives.Eligible women will be randomised to either mifepristone followed by 4 days of placebo or mifepristone followed by four days of ethinyl oestradiol. Women will undergo vaginal ultrasound to assess follicular size, assessment of cervical mucus quality and have blood taken for serum levels of oestradiol and progesterone 2 days before commencing treatment, on the third treatment day, 6 days after starting treament and then twice weekly for 3 weeks. Women will be required to use condoms for the duration of the study.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
35340
0
Query!
Address
35340
0
Query!
Country
35340
0
Query!
Phone
35340
0
Query!
Fax
35340
0
Query!
Email
35340
0
Query!
Contact person for public queries
Name
9919
0
Dr Edith Weisberg
Query!
Address
9919
0
Sydney Centre for Reproductive Health Research
Research Division
FPA Health
328-336 Liverpool Road
Ashfield NSW 2131
Query!
Country
9919
0
Australia
Query!
Phone
9919
0
+61 2 87524342
Query!
Fax
9919
0
+61 2 97165073
Query!
Email
9919
0
[email protected]
Query!
Contact person for scientific queries
Name
847
0
Professor Ian Fraser
Query!
Address
847
0
Queen Elizabeth Research Institute
University of Sydney
Camperdown NSW 2006
Query!
Country
847
0
Australia
Query!
Phone
847
0
+61 2 93512478
Query!
Fax
847
0
+61 2 93514560
Query!
Email
847
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF